Hypothesis

Age‑dependent accumulation of N6‑methyladenosine (m6A) in the 3′UTRs of synaptic genes functions as a homeostatic brake that dampens excitatory translation and protects neuronal networks from activity‑induced stress. When this brake fails—marked by reduced METTL3/14 activity and loss of m6A—excitation/inhibition balance tilts toward hyperactivity, driving proteostatic collapse and neurodegeneration.

Mechanistic Rationale

• In cognitively normal aging, m6A rises on transcripts encoding G3BP1/2, ARC, and vesicular‑release proteins (1). m6A in GGACU motifs repels stress‑granule nucleators, shortening mRNA half‑life and limiting translation of proteins that promote synaptic excitation (3).
• YTHDF2‑mediated decay of these m6A‑marked transcripts reduces nascent excitatory scaffolding, thereby lowering postsynaptic calcium load and attenuating activity‑dependent ROS production.
• In Alzheimer’s disease, METTL3/14 immunoreactivity drops and the enzyme redistributes to the cytosol (2). Loss of m6A lifts translational repression, leading to excess ARC, G3BP1, and glutamate‑transport proteins, which destabilize synapses and trigger ubiquitin‑proteasome overload (1,4).

Thus, the age‑related m6A increase is not a passive damage marker but an active, tunable inhibitory circuit that the cell employs to preserve proteostasis. Its failure converts a protective mechanism into a driver of pathology.

Testable Predictions

1. **Genetic elevation of METTL3 in the hippocampus of aged (≥18 mo) wild‑type mice will restore 3′UTR m6A levels on excitatory‑synapse transcripts, decrease their translation (measured by puromycin‑associated nascent chain labeling), and lower spontaneous cortical firing rates in vivo.
2. These mice will exhibit improved performance on hippocampal‑dependent memory tasks (Morris water maze, novel object recognition) relative to age‑matched controls.
3. Median lifespan will be extended by ≥10 % compared with littermate controls, without causing developmental defects.
4. Conversely, neuron‑specific METTL3 knock‑down in middle‑aged (12 mo) mice will precipitate premature loss of m6A, heightened excitatory‑synapse protein expression, EEG‑detectable hyperactivity, accelerated memory decline, and shortened lifespan.

Experimental Design

• Use AAV‑CamKII‑METTL3 or AAV‑CamKII‑shMETTL3 for targeted hippocampal overexpression or knockdown.
• Validate m6A changes by MeRIP‑seq on isolated synaptosomal RNA; quantify translation via RiboPURO or SUnSET.
• In vivo cortical activity assessed with chronic EEG or two‑photon calcium imaging of excitatory neurons.
• Behavioral battery administered at 3‑month intervals post‑treatment.
• Survival monitored until natural death; Cox proportional hazards model to assess hazard ratios.

Falsifiability

If METTL3 overexpression does not increase synaptic 3′UTR m6A, fails to reduce excitatory‑protein translation, does not alter network activity, and confers no cognitive or survival benefit, the hypothesis that age‑related m6A acts as a protective translational brake is falsified. Likewise, if METTL3 knock‑down produces no exacerbation of excitability or pathology, the proposed direction of causality is refuted.

This framework transforms the observation of rising m6A with healthy aging from a correlative stress signature into a mechanistic, evolutionarily tuned restraint on neuronal excitability—one that longevity interventions could potentiate rather than override.